Published in Proc Natl Acad Sci U S A on July 05, 2000
Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest (2000) 3.15
From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev (2010) 3.11
Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein. Mol Biol Cell (2003) 3.11
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest (2003) 3.09
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev (2007) 2.82
A crucial role for thiol antioxidants in estrogen-deficiency bone loss. J Clin Invest (2003) 2.37
Osteoimmunology: interactions of the bone and immune system. Endocr Rev (2008) 2.32
Disorders of bone remodeling. Annu Rev Pathol (2011) 2.05
The unitary model for estrogen deficiency and the pathogenesis of osteoporosis: is a revision needed? J Bone Miner Res (2011) 1.95
The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol (2010) 1.79
Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci U S A (2003) 1.75
Suppressive function of androgen receptor in bone resorption. Proc Natl Acad Sci U S A (2003) 1.72
The mechanisms of estrogen regulation of bone resorption. J Clin Invest (2000) 1.66
Estrogen and the skeleton. Trends Endocrinol Metab (2012) 1.46
A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc Natl Acad Sci U S A (2002) 1.27
IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci U S A (2001) 1.26
Female reproductive system and bone. Arch Biochem Biophys (2010) 1.19
Human primary osteoclasts: in vitro generation and applications as pharmacological and clinical assay. J Transl Med (2004) 1.15
Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci (2012) 1.12
Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol (2013) 1.10
Physiology of bone loss. Radiol Clin North Am (2010) 1.09
c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest (2006) 1.08
Role of MKP-1 in osteoclasts and bone homeostasis. Am J Pathol (2009) 1.07
Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos. Mol Endocrinol (2005) 1.06
Exploring the mechanisms regulating regeneration of deer antlers. Philos Trans R Soc Lond B Biol Sci (2004) 1.05
Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem (2012) 1.05
Estrogen and bone: insights from estrogen-resistant, aromatase-deficient, and normal men. Bone (2008) 1.01
Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol Endocrinol (2009) 1.01
Conditional inactivation of noggin in the postnatal skeleton causes osteopenia. Endocrinology (2012) 1.01
Deer antlers: a zoological curiosity or the key to understanding organ regeneration in mammals? J Anat (2005) 0.99
Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling. J Biol Chem (2013) 0.98
Regulation of bone turnover by sex steroids in men. J Bone Miner Res (2008) 0.95
Stimulation of bone formation in cortical bone of mice treated with a receptor activator of nuclear factor-κB ligand (RANKL)-binding peptide that possesses osteoclastogenesis inhibitory activity. J Biol Chem (2013) 0.94
Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice. J Bone Miner Res (2009) 0.92
FSH and TSH in the regulation of bone mass: the pituitary/immune/bone axis. Clin Dev Immunol (2013) 0.92
Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. Rheumatol Int (2008) 0.91
Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss. Proc Natl Acad Sci U S A (2003) 0.90
Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol Spectr (2016) 0.88
Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer. Int J Clin Oncol (2008) 0.87
Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol (2007) 0.87
Biological agents in management of osteoporosis. Eur J Clin Pharmacol (2014) 0.86
Nuclear receptors in bone physiology and diseases. Physiol Rev (2013) 0.86
The oxytocin-bone axis. J Neuroendocrinol (2014) 0.85
Deregulation of bone forming cells in bone diseases and anabolic effects of strontium-containing agents and biomaterials. Biomed Res Int (2014) 0.85
Mechanisms of bone anabolism regulated by statins. Biosci Rep (2012) 0.85
TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women. Menopause (2010) 0.83
High molecular weight tropomyosins regulate osteoclast cytoskeletal morphology. Bone (2008) 0.83
HIV and Bone Disease: A Perspective of the Role of microRNAs in Bone Biology upon HIV Infection. J Osteoporos (2013) 0.83
Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporos Int (2008) 0.82
Japanese medaka: a non-mammalian vertebrate model for studying sex and age-related bone metabolism in vivo. PLoS One (2014) 0.81
Dual Effect of Chrysanthemum indicum Extract to Stimulate Osteoblast Differentiation and Inhibit Osteoclast Formation and Resorption In Vitro. Evid Based Complement Alternat Med (2014) 0.81
Isoflavones and skeletal health: are these molecules ready for clinical application? Osteoporos Int (2003) 0.81
Receptor activator of nuclear factor-kappaB ligand-induced nuclear factor of activated T cells (C1) autoregulates its own expression in osteoclasts and mediates the up-regulation of tartrate-resistant acid phosphatase. Mol Endocrinol (2007) 0.81
Minireview: nuclear receptor regulation of osteoclast and bone remodeling. Mol Endocrinol (2014) 0.80
Bone mass regulation of leptin and postmenopausal osteoporosis with obesity. Clin Cases Miner Bone Metab (2012) 0.80
Characterization of functional reprogramming during osteoclast development using quantitative proteomics and mRNA profiling. Mol Cell Proteomics (2014) 0.79
Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int (2004) 0.77
Disruption of claudin-18 diminishes ovariectomy-induced bone loss in mice. Am J Physiol Endocrinol Metab (2013) 0.77
Interaction between bone and muscle in older persons with mobility limitations. Curr Pharm Des (2014) 0.77
Oxytocin and bone. Am J Physiol Regul Integr Comp Physiol (2014) 0.76
Proteomic Analysis of Estrogen-Mediated Signal Transduction in Osteoclasts Formation. Biomed Res Int (2015) 0.75
Ncf1 affects osteoclast formation but is not critical for postmenopausal bone loss. BMC Musculoskelet Disord (2016) 0.75
Evidence for estrogen receptor expression during medullary bone formation and resorption in estrogen-treated male Japanese quails (Coturnix coturnix japonica). J Vet Sci (2012) 0.75
Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats. PLoS One (2017) 0.75
Extra virgin olive oil in maternal diet increases osteogenic genes expression, but high amounts have deleterious effects on bones in mice offspring at adolescence. Iran J Basic Med Sci (2016) 0.75
Potential Role of Local Estrogen in Enhancement of Fracture Healing: Preclinical Study in Rabbits. Arch Bone Jt Surg (2016) 0.75
Discovery of a New Class of Cathepsin K Inhibitors in Rhizoma Drynariae as Potential Candidates for the Treatment of Osteoporosis. Int J Mol Sci (2016) 0.75
Interleukin-15-activated natural killer cells kill autologous osteoclasts via LFA-1, DNAM-1 and TRAIL, and inhibit osteoclast-mediated bone erosion in vitro. Immunology (2015) 0.75
Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling? Curr Pharmacogenomics Person Med (2008) 0.75
Pathogenesis of Osteoporosis. Transl Endocrinol Metab (2010) 0.75
[New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?]. Z Rheumatol (2006) 0.75
The effect of vitamin K2 on bone metabolism in aged female rats. Osteoporos Int (2005) 0.75
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell (1998) 17.76
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A (1998) 12.61
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta (1991) 11.78
The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell (1998) 9.96
Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (1997) 9.09
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev (1999) 7.06
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A (1999) 5.78
Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev (1997) 5.65
Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med (1995) 5.27
Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science (1992) 5.18
TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem (1997) 4.61
Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med (1996) 2.92
Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res (1996) 2.73
Regulation and function of the JNK subgroup of MAP kinases. Biochim Biophys Acta (1997) 2.72
Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol (1995) 2.71
Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem (1998) 2.48
17 beta-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest (1992) 2.43
Transcriptional regulation in the immune system: all roads lead to AP-1. J Leukoc Biol (1998) 2.16
Cell biology of the osteoclast. Exp Hematol (1999) 1.99
Tripartite steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones. Mol Endocrinol (1996) 1.96
Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol (1999) 1.96
Skeletal effects of estrogen. Endocr Rev (1994) 1.91
Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology (1998) 1.75
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest (1994) 1.55
Estrogen decreases TNF gene expression by blocking JNK activity and the resulting production of c-Jun and JunD. J Clin Invest (1999) 1.50
Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J Clin Invest (1994) 1.50
The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res (1997) 1.42
Estradiol down-regulates LPS-induced cytokine production and NFkB activation in murine macrophages. Am J Reprod Immunol (1997) 1.38
The effective free fraction of estradiol and xenoestrogens in human serum measured by whole cell uptake assays: physiology of delivery modifies estrogenic activity. Proc Soc Exp Biol Med (1998) 1.08
Steroidal pure antioestrogens. J Endocrinol (1987) 1.05
Selective estrogen receptor modulators: clinical spectrum. Endocr Rev (1999) 1.03
Estrogen modulation of avian osteoclast lysosomal gene expression. Endocrinology (1993) 1.01
Hormonal regulation of osteoclast function. Trends Endocrinol Metab (2008) 1.00
Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med (1994) 0.96
Ovariectomy augments B lymphopoiesis and generation of monocyte-macrophage precursors in rat bone marrow. Am J Physiol (1998) 0.95
Estrogen modulates the recruitment of myelopoietic cell progenitors in rat through a stromal cell-independent mechanism involving apoptosis. Blood (1996) 0.87
Tissue-selective actions of estrogen analogs. Bone (1995) 0.83
17beta-estradiol induces apoptosis in the preosteoclastic FLG 29.1 cell line. Biochem Biophys Res Commun (1999) 0.82
Characterization of the 5'-flanking region of the human tartrate-resistant acid phosphatase (TRAP) gene. Bone (1995) 0.81
Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A (1988) 3.53
Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. Science (1987) 2.71
Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. Cell (1990) 2.68
Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol (1994) 2.62
Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. Proc Natl Acad Sci U S A (1989) 2.31
Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science (1988) 2.15
1,25-Dihydroxyvitamin D3-induced differentiation in a human promyelocytic leukemia cell line (HL-60): receptor-mediated maturation to macrophage-like cells. J Cell Biol (1984) 2.01
Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology (2000) 1.93
The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev (1999) 1.84
Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol (1995) 1.75
Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol (1997) 1.63
The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. J Biol Chem (1990) 1.49
Vitamin D receptor interaction with specific DNA requires a nuclear protein and 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci U S A (1990) 1.42
Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J Biol Chem (1993) 1.38
A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet (1991) 1.34
The caudal-related homeodomain protein Cdx-2 regulates vitamin D receptor gene expression in the small intestine. J Bone Miner Res (1999) 1.31
An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. Proc Natl Acad Sci U S A (1989) 1.29
Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. Mol Endocrinol (1989) 1.27
1,25-Dihydroxyvitamin D3 receptors in rat kidney cytosol. Biochem Biophys Res Commun (1979) 1.27
IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci U S A (2001) 1.26
Identification of the poly(C) binding protein in the complex associated with the 3' untranslated region of erythropoietin messenger RNA. Blood (1999) 1.23
Immunocytochemical detection of 1,25-dihydroxyvitamin D receptors in normal human tissues. J Clin Endocrinol Metab (1988) 1.22
1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology (1997) 1.19
Monoclonal antibodies to chick intestinal receptors for 1,25-dihydroxyvitamin D3. Interaction and effects of binding on receptor function. J Biol Chem (1984) 1.17
Avian and mammalian receptors for 1,25-dihydroxyvitamin D3: in vitro translation to characterize size and hormone-dependent regulation. Proc Natl Acad Sci U S A (1987) 1.16
Purification of chicken intestinal receptor for 1,25-dihydroxyvitamin D. Proc Natl Acad Sci U S A (1979) 1.15
Failure of bromocriptine to maintain reduction in size of a macroprolactinoma. Br Med J (Clin Res Ed) (1983) 1.14
Hormone-dependent phosphorylation of the 1,25-dihydroxyvitamin D3 receptor in mouse fibroblasts. Biochem Biophys Res Commun (1985) 1.14
Reconstitution of the vitamin D-responsive osteocalcin transcription unit in Saccharomyces cerevisiae. Mol Cell Biol (1989) 1.13
Serum and monoclonal antibodies against the chick intestinal receptor for 1,25-dihydroxyvitamin D3. Generation by a preparation enriched in a 64,000-dalton protein. J Biol Chem (1983) 1.10
Vitamin D receptor interaction with specific DNA. Association as a 1,25-dihydroxyvitamin D3-modulated heterodimer. J Biol Chem (1991) 1.10
Association of 1,25-dihydroxyvitamin D3 with cultured 3T6 mouse fibroblasts. Cellular uptake and receptor-mediated migration to the nucleus. J Biol Chem (1983) 1.08
Expression of human vitamin D receptor in Saccharomyces cerevisiae. Purification, properties, and generation of polyclonal antibodies. J Biol Chem (1990) 1.08
Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res (1991) 1.06
The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families. J Clin Invest (1990) 1.06
Biochemical evidence for 1,25-dihydroxyvitamin D receptor macromolecules in parathyroid, pancreatic, pituitary, and placental tissues. Life Sci (1980) 1.06
Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology (1988) 1.06
Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J Clin Endocrinol Metab (2000) 1.01
Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. J Clin Endocrinol Metab (1989) 1.01
The inhibitory effect of interleukin-10 on mouse osteoclast formation involves novel tyrosine-phosphorylated proteins. J Bone Miner Res (2000) 1.01
Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology (2001) 1.01
Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest (1990) 1.00
Elevated serum levels of 1alpha, 25-dihydroxycholecalciferol in lactating rats. Nature (1977) 0.99
A unique point mutation in the human vitamin D receptor chromosomal gene confers hereditary resistance to 1,25-dihydroxyvitamin D3. Mol Endocrinol (1990) 0.99
Analysis of osteocalcin expression in transgenic mice reveals a species difference in vitamin D regulation of mouse and human osteocalcin genes. J Bone Miner Res (1997) 0.98
Development of hybridomas secreting monoclonal antibodies to the chicken intestinal 1 alpha,25-dihydroxyvitamin D3 receptor. Proc Natl Acad Sci U S A (1982) 0.97
A 55-kilodalton accessory factor facilitates vitamin D receptor DNA binding. Mol Endocrinol (1991) 0.97
Immunocytology with microwave-fixed fibroblasts shows 1 alpha,25-dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors. J Cell Biol (1990) 0.96
The ovary: a target organ for 1,25-dihydroxyvitamin D3. Endocrinology (1983) 0.96
Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptor in breast cancer. Cancer Res (1987) 0.94
The human osteocalcin promoter directs bone-specific vitamin D-regulatable gene expression in transgenic mice. Mol Endocrinol (1993) 0.94
Vitamin D3--resistant fibroblasts have immunoassayable 1,25-dihydroxyvitamin D3 receptors. Science (1984) 0.94
An improved radioreceptor assay for 1,25-dihydroxyvitamin D in human plasma. Anal Biochem (1981) 0.93
Chicken intestinal receptor for 1,25-dihydroxyvitamin D3. Immunologic characterization and homogeneous isolation of a 60,000-dalton protein. J Biol Chem (1987) 0.93
Trypsin cleavage of chick 1,25-dihydroxyvitamin D3 receptors. Generation of discrete polypeptides which retain hormone but are unreactive to DNA and monoclonal antibody. J Biol Chem (1985) 0.92
The genomic mechanism of action of 1,25-dihydroxyvitamin D3. J Bone Miner Res (1991) 0.91
Cell- and stage-specific expression of vitamin D receptor and calbindin genes in rat incisor: regulation by 1,25-dihydroxyvitamin D3. Dev Biol (1993) 0.90
Effect of growth hormone on vitamin D metabolism. Nature (1978) 0.90
Effect of hormones and development on the expression of the rat 1,25-dihydroxyvitamin D3 receptor gene. Comparison with calbindin gene expression. J Biol Chem (1989) 0.89
Hormonal effects of vitamin D3 on epidermal melanocytes. J Cell Physiol (1988) 0.89
Intracellular receptors mediate the biologic action of 1,25-dihydroxyvitamin D3. Nutr Rev (1985) 0.89
Inhibition of vitamin D receptor-retinoid X receptor-vitamin D response element complex formation by nuclear extracts of vitamin D-resistant New World primate cells. Endocrinology (1996) 0.89
Enhanced activity of osteoblast differentiation factor (PEBP2alphaA2/CBFa1) in affected sutural osteoblasts from patients with nonsyndromic craniosynostosis. Cleft Palate Craniofac J (2001) 0.89
Molecular action of 1,25-dihydroxyvitamin D3: new cultured cell models. Ann N Y Acad Sci (1981) 0.89
A new point mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor in a kindred with hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab (1993) 0.88
Sensitive and specific detection of retinoid receptor subtype proteins in cultured cell and tumor extracts. Mol Endocrinol (1994) 0.88
Genetic defects of the 1,25-dihydroxyvitamin D3 receptor. J Recept Res (1991) 0.88
Identification of a novel mutation in hereditary vitamin D resistant rickets causing exon skipping. Clin Endocrinol (Oxf) (1996) 0.88
Positive regulation of the vitamin D receptor by its cognate ligand in heterologous expression systems. Mol Endocrinol (1993) 0.88
Distribution and subcellular immunolocalization of 1,25-dihydroxyvitamin D3 receptors in rat epiphyseal cartilage. Cell Mol Biol (Noisy-le-grand) (1993) 0.87
Mutant vitamin D receptors which confer hereditary resistance to 1,25-dihydroxyvitamin D3 in humans are transcriptionally inactive in vitro. J Biol Chem (1989) 0.87
Circulating 1alpha,25-dihydroxyvitamin D in the chicken: enhancement by injection of prolactin and during egg laying. Life Sci (1976) 0.87
Influence of estrogen on renal vitamin D hydroxylases and serum 1alpha,25-(OH)2D3 in chicks. Am J Physiol (1978) 0.87
Estrogen modulates the recruitment of myelopoietic cell progenitors in rat through a stromal cell-independent mechanism involving apoptosis. Blood (1996) 0.87
Ultrastructural immunocytochemical localization of endogenous 1,25-dihydroxyvitamin D3 and its receptors in osteoblasts and osteocytes from neonatal mouse and rat calvaria. Bone Miner (1987) 0.86
The vitamin D receptor: a primitive steroid receptor related to thyroid hormone receptor. J Steroid Biochem (1988) 0.86
1,25-dihydroxyvitamin D3 receptors in rat lung during the perinatal period: regulation and immunohistochemical localization. Endocrinology (1990) 0.85
Dynamic changes in circulating 1,25-dihydroxyvitamin D during reproduction in rats. Science (1979) 0.85
Vitamin D metabolites in adolescents and young adults with cystic fibrosis: effects of sun and season. J Pediatr (1985) 0.84
Evidence for a reactive sulfhydryl in the DNA binding domain of the 1,25-dihydroxyvitamin D3 receptor. Biochem Biophys Res Commun (1981) 0.84
Use of chick kidney to enzymatically generate radiolabeled 1,25-dihydroxyvitamin D and other vitamin D metabolites. Methods Enzymol (1980) 0.84
1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. Biochemistry (1994) 0.84
Interaction between 1,25-dihydroxyvitamin D3 receptors and intestinal nuclei. Binding to nuclear constituents in vitro. J Biol Chem (1982) 0.83
Receptors for 1,25-dihydroxyvitamin D3 in chick pancreas: a partial physical and functional characterization. J Steroid Biochem (1982) 0.83
Transcriptional activation and dimerization functions in the human vitamin D receptor. Mol Endocrinol (1996) 0.83
Human vitamin D receptor-dependent transactivation in Saccharomyces cerevisiae requires retinoid X receptor. Mol Endocrinol (1996) 0.82
1,25-Dihydroxyvitamin D3 induces 25-hydroxyvitamin D3-24-hydroxylase in a cultured monkey kidney cell line (LLC-MK2) apparently deficient in the high affinity receptor for the hormone. J Biol Chem (1984) 0.82
Tissue specificity and mechanism of vitamin D receptor up-regulation during dietary phosphorus restriction in the rat. J Bone Miner Res (1995) 0.82
Immunochemical detection of unique proteolytic fragments of the chick 1,25-dihydroxyvitamin D3 receptor. Distinct 20-kDa DNA-binding and 45-kDa hormone-binding species. J Biol Chem (1987) 0.82
Leukemia inhibitory factor as a mediator of JAK/STAT activation in murine osteoblasts. J Bone Miner Res (1995) 0.82
Retinoid X receptor acts as a hormone receptor in vivo to induce a key metabolic enzyme for 1,25-dihydroxyvitamin D3. J Biol Chem (1995) 0.81
Role of prolactin in vitamin D metabolism and calcium absorption during lactation in the rat. J Endocrinol (1982) 0.80
Calcium metabolism during lactation: enhanced intestinal calcium absorption in vitamin D-deprived, hypocalcemic rats. Endocrinology (1981) 0.79
Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226. Cancer Res (1988) 0.79
Overexpression of the human vitamin D3 receptor in mammalian cells using recombinant adenovirus vectors. Mol Endocrinol (1991) 0.78
1,25-Dihydroxyvitamin D3 inhibits the clonogenic growth of transformed cells via its receptor. Biochem Biophys Res Commun (1986) 0.78
Bone vitamin D-dependent calcium-binding protein is localized in chondrocytes of growth-plate cartilage. Calcif Tissue Int (1986) 0.78